Rhabdomyosarcoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Rhabdomyosarcoma – Drugs In Development, 2023’, provides an overview of the Rhabdomyosarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews pipeline therapeutics for Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rhabdomyosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbisko Therapeutics Co Ltd
AbbVie Inc
Actuate Therapeutics Inc
Aptadel Therapeutics SL
AstraZeneca Plc
Bayer AG
Biogenera SpA
Bristol-Myers Squibb Co
Cellectar Biosciences Inc
Children's National Research Institute
Edison Oncology Holding Corp
Eisai Co Ltd
Evgen Pharma Plc
Exelixis Inc
F. Hoffmann-La Roche Ltd
GAiA BioMedicine Inc
Gate2Brain SL
Hutchison MediPharma Ltd
Immatics NV
Immix BioPharma Inc
Immugenia Inc
Iproteos SL
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Kronos Bio Inc
Lantern Pharma Inc
Lirum Therapeutics Inc
MacroGenics Inc
Mana Therapeutics Inc
Manhattan Biosolutions Inc
Medosome Biotec LLC
Mirati Therapeutics Inc
NanoRED Biotechnology
Nationwide Children's Hospital
neoX Biotech (HK) Ltd
North Carolina Central University
Novartis AG
NovoMedix LLC
Ohara Pharmaceutical Co Ltd
Ohio State University
Oncoheroes Biosciences Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Orgenesis Inc
Orphelia Pharma SAS
Peel Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
Provectus Biopharmaceuticals Inc
SELLAS Life Sciences Group Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shepherd Therapeutics Inc
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Taiwan Liposome Co Ltd
Talus Bioscience Inc
Tyra Biosciences Inc
U.S. National Institutes of Health
University Hospital Tubingen
University of California San Francisco
University of South Australia
Veana Therapeutics LLC